Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults

Surabhi B Vora(University of Washington), Joshua A. Hill(Seattle Pacific University), Alpana Waghmare(Seattle Children's Hospital), Janet A. Englund(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Pingping Qu(Cancer Research And Biostatistics)
Open Forum Infectious Diseases
April 9, 2020
10.1093/ofid/ofaa121
Cited by 149

Related Papers

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Current concepts in the diagnosis and management of cytokine release syndrome
|Blood|2014|2.8k
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
|Blood|2017|564
Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
|Blood|2018|492
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
|Leukemia|2018|452